CXCR4 and cancer: Here, simultaneous agonist-dependent activation of CXCR4 and CB2 resulted in reduced CXCR4-mediated formation of phosphorylated p42/44 MAPK (P-p42/44) and ultimately diminished cancer cell chemotaxis.